CROI 2014: HCV Abstract and Poster Presentation Coverage by Jules Levin (NATAP)

21st Conference on Retroviruses and
Opportunistic Infections
Boston MA
March 3 - 6, 2014

Reported by Jules Levin

(All links open into new windows)

• ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage - (03/05/14)
• ABT-530, an HCV NS5A Inhibitor With Potent Pangenotypic Activity and High Genetic Barrier to Resistance - (03/05/14)
• All-Oral Combination of Daclatasvir, Asunaprevir, and BMS-791325 for HCV Genotype 1 Infection - (03/04/14)
• Daclatasvir in Combination With Simeprevir With or Without Ribavirin for Hepatitis C Virus Genotype 1 Infection - (03/04/14)
• All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1) - (03/04/14)
• Three-DAA Regimen (Abbvie) Achieves 99% SVR12 Rates in HCV Genotype 1b Naives - written by Mark Mascolini - (03/04/14)
• Simeprevir Plus PegIFN/RBV Yields 74% SVR12 in HCV/HIV Patients - written by Mark Mascolini - (03/04/14)
• SVR12 72% With Faldaprevir Plus PegIFN/RBV in Naives With HCV/HIV - written by Mark Mascolini - (03/04/14)
• Combination Oral, Hepatitis C Antiviral Therapy for 6 or 12 Weeks: Results of the SYNERGY Trial - (03/04/14)
• Simeprevir plus PegIFN/ribavirin in HCV genotype-1/HIV-1 co-infection (Study C212) - (03/04/14)
• Double or Triple DAA Therapy for HCV-1 Yields 95-100% SVRs in 6 or 12 Weeks (SYNERGY Study) - written by Mark Mascolini - (03/04/14)
• PEARL III: SVR ≥99% AFTER 12 WKS OF ABT-450/R/267 + ABT-333 ± RBV IN TREATMENT-NAIVE HCV GT1B INFECTION - (03/04/14)

Source NATAP